Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 858M 744M 698M 636M 1.2B 81.93B 1.22B 8.21B 3.21B 41.01B 3.22B 3.15B 137B P/E 2026 *
9.3x
P/E 2027 * 7.64x
Enterprise Value 1.16B 1.01B 944M 861M 1.62B 111B 1.65B 11.12B 4.34B 55.51B 4.36B 4.27B 185B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.33x
Free-Float
47.23%
Yield 2026 *
-
Yield 2027 * -
1 day+2.73%
1 week-0.91%
Current month+3.26%
1 month+9.49%
3 months+19.02%
6 months-27.63%
Current year-23.11%
1 week 19.55
Extreme 19.55
20.9
1 month 18.5
Extreme 18.5
22.64
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
65.92
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 1996-02-28
Chief Operating Officer 76 1996-02-28
Director of Finance/CFO 58 2014-03-31
Director TitleAgeSince
Chairman 76 1996-02-28
Director/Board Member 79 1996-02-28
Director/Board Member 58 2022-08-03
Date Insider Type Main position Quantity % Market Cap.
8/11/26 Sell

Director

-7,973 0.0181%
8/7/26 Fiscal year

Chief Financial Officer

18,286 0.0415%
7/9/26 Free

Director

24,532 0.0556%
Change 5-day change 1-year change 3-year change Capi.($)
+2.73%-0.91%-31.84%-61.92% 858M
-2.25%-0.09%+73.08%+120.19% 1,078B
-0.71%+0.34%+48.87%+49.97% 632B
-0.63%+1.21%+21.66%+63.53% 443B
-1.99%-3.19%+42.18%+34.26% 356B
-1.20%-2.98%+23.99%+34.43% 289B
-2.13%-3.61%-1.03%+3.17% 245B
-1.39%+0.15%+41.78%+57.71% 226B
-1.19%-3.41%-9.18%-52.41% 204B
-0.43%+3.25%+15.56%+72.25% 171B
Average -0.93%+1.48%+22.51%+32.12% 364.46B
Weighted average by Cap. -1.49%+1.30%+41.47%+62.25%

Financials

2026 *2027 *
Net sales 748M 648M 608M 554M 1.04B 71.36B 1.06B 7.15B 2.79B 35.72B 2.81B 2.75B 119B 784M 680M 637M 581M 1.09B 74.86B 1.11B 7.5B 2.93B 37.47B 2.94B 2.88B 125B
Net income 99.32M 86.09M 80.7M 73.59M 138M 9.48B 141M 950M 371M 4.74B 373M 365M 15.83B 115M 100M 93.79M 85.51M 161M 11.02B 163M 1.1B 431M 5.51B 433M 424M 18.39B
Net Debt 303M 263M 247M 225M 423M 28.96B 430M 2.9B 1.13B 14.5B 1.14B 1.11B 48.36B 184M 160M 150M 136M 257M 17.57B 261M 1.76B 688M 8.8B 691M 676M 29.35B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
26-08-14 US$20.59 +2.03% 44,432
26-08-13 US$20.18 +1.00% 526,116
26-08-12 US$19.98 -2.15% 343,843
26-08-11 US$20.42 +0.54% 570,493
26-08-10 US$20.31 -2.26% 645,749
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
20.18USD
Average target price
22.00USD
Spread / Average Target
+9.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock